TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01505530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2495655
Description: Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care Chemotherapy
Description: Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care Chemotherapy
Description: Standard of care, gemcitabine-based regimen (single-agent gemcitabine or gemcitabine plus erlotinib) or FOLFIRINOX (combination chemotherapy regimen including 5-fluorouracil, leucovorin, oxaliplatin, and irinotecan). The choice of gemcitabine-based regimen or FOLFIRINOX will be determined by the investigator (based on the standard of care used at the treating institution or as directed by local regulatory authorities).
Study: NCT00845156

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid
Description: Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha Lipoic Acid
Description: Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
Study: NCT04270305

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orientation
Description: In the first group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve navigation competences and orientation. During walk in VR environment with labyrinths of increasing complexity. Exercises include abilities such as orienting in complex environments, perceiving distance and planning routes to distant locations. The presence of landmarks has been included in some exercises to facilitate allocentric orientation strategies.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walking
Description: In the second group CP patients undergo a four week training with once daily sessions lasting 30 minutes. The treatment includes exercises to improve walking and balance abilities. Using engaging VR environments (e.g. transfer your load from the left to the right side to avoid obstacles while skiing; shoot balls at targets inside an area; walk in a forest as fast as possible; hit as many elves as possible by squatting, and so on). No exercises for orientation are included in this group.
Study: NCT00302705

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan, Enalapril
Description: 160 mg valsartan versus 10-20 mg enalapril

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan, Enalapril
Description: 160 mg valsartan versus 10-20 mg enalapril

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ambulatory blood pressure monitoring
Description: Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Missing one dose
Description: Patients skip the dose the second day of monitoring

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Missing one dose
Description: Patients skip the dose the second day of monitoring
Study: NCT02528760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metaclopramide
Description: 23. Metoclopromide to be given 10mg iv 8 hourly

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythromycin
Description: Erythromycin to be given 70mg iv 12 hourly.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00677118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin,fluorouracil
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
Study: NCT01141465

Intervention type: DRUG
Intervention: Fluticasone / formoterol metered dose inhaler
Description: Prescribed at the same BDP-equivalent dose as baseline ICS

Intervention type: DRUG
Intervention: Fluticasone / salmeterol dry powder inhaler
Description: Prescribed at the same BDP-equivalent dose as baseline ICS

Intervention type: DRUG
Intervention: Budesonide / formoterol dry powder inhaler
Description: Prescribed at the same BDP-equivalent dose as baseline ICS

Intervention type: DRUG
Intervention: Fluticasone / salmeterol dry powder inhaler
Description: Prescribed at ≥twice BDP-equivalent dose as baseline ICS

Intervention type: DRUG
Intervention: Fluticasone / salmeterol metred dose inhaler
Description: Prescribed at ≥twice BDP-equivalent dose as baseline ICS

Intervention type: DRUG
Intervention: BUD/FOR dry powder inhaler
Description: Prescribed at ≥twice BDP-equivalent dose as baseline ICS
Study: NCT02063295

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ZGN-440 sterile diluent
Description: ZGN-440 sterile diluent/placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZGN-440 for injectable suspension
Study: NCT00973700

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MF59-eH1N1_f
Description: MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eH1N1_f
Description: Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: eH1N1_f
Description: Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
Study: NCT01894711

Intervention type: DRUG
Intervention: Trastuzumab
Description: Treatment with trastuzumab in HER2 positive patients
Study: NCT00847548

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: substance abuse/domestic violence treatment
Description: This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT addressing partner violence
Description: This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
Study: NCT02403752

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Paired PLIE Program
Description: Integrative exercise as described above
Study: NCT03757364

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis

Intervention type: DRUG
Intervention: Methotrexate
Description: Methotrexate in the treatment of distal interphalangeal joint extensor tendon enthesopathy in patients with nail psoriasis
Study: NCT03735758

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pazopanib or guideline conform chemotherapy
Description: Pazopanib (800mg/each day) or guideline conform chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pazopanib or guideline conform chemotherapy
Description: Pazopanib (800mg/each day) or guideline conform chemotherapy
Study: NCT02512666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AM4113-N5UT Dino-Lite
Study: NCT03165552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acute kidney injury education
Description: A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
Study: NCT02468739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganglioside-monosialic acid
Description: Ganglioside-monosialic sodium is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2). The dosages of GM1 are 80mg per day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo is added into to 250 ml of 0.9% sodium chloride injection, which is given once a day via intravenous drip infusion for 3 days. The first dose is given at 1 day before the start of the chemotherapy.(day -1, day 1 and day2).
Study: NCT00602329

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxaliplatin
Description: Given IV
Study: NCT05532085

Intervention type: OTHER
Intervention: Evaluation of pain during voluntary termination of pregnancy with medication following consideration of predictive factors of pain without an established analgesic protocol
Description: Evaluation of the pain felt by women having an abortion by aspiration under local anes!thesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.

Intervention type: OTHER
Intervention: Evaluation of pain during a voluntary medical termination of pregnancy following consideration of predictive factors of pain with an established analgesic protocol
Description: Evaluation of the pain felt by women having a medical abortion following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during a medical abortion will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.

Intervention type: OTHER
Intervention: Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain without an established analgesic protocol
Description: Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.

Intervention type: OTHER
Intervention: Assessment of pain during voluntary termination of pregnancy by aspiration under local anesthesia following consideration of predictive factors of pain with established analgesic protocol
Description: Evaluation of the pain felt by women having an abortion by aspiration under local anesthesia following the application of an analgesic protocol indexed on the predictive factors of pain.~The intensity of the pain of patients during an abortion by aspiration under local anesthesia will be quantified by a Visual Analogue Scale (VAS) at the time of the abortion and in the following 4 days.
Study: NCT00583258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alfuzosin (Xatral)
Description: 10 mg PO once a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Alfuzosin
Description: 10 mg PO once a day
Study: NCT03388320

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A-CHESS
Description: Use of smartphone application: Addiction Comprehensive Health Enhancement Support System (A-CHESS)
Study: NCT00483899

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GW870086X will be administered by subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GW870086X will be administered by subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching GW870086X will be administered by subjects
Study: NCT01913990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone, Ondansetron, Aprepitant
Description: Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.

Intervention type: OTHER
Group type: OTHER
Intervention: Arm A: Standard Anti-emetic regimen
Description: Treating physician's discretion for type of anti-emetic to be prescribed.
Study: NCT04314869

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterus transplantation
Description: Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.
Study: NCT03955770

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (HFOT)
Description: HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: High-flow oxygen therapy (HFOT)
Description: HFOT will be applied by a dedicated large bore nasal cannula (Optiflow+, Fisher\&Paykel, New Zealand) at a flow rate 60 L/min, FiO2 45%, temperature 32 °C, using a HFOT device (myAIRVO2, Fisher\&Paykel, New Zealand).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen therapy (LFOT)
Description: LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Low-flow oxygen therapy (LFOT)
Description: LFOT will be provided by a standard nasal cannula at a flow rate of 3 L/min using an oxygen concentrator (EverFlow, Philips Respironics).
Study: NCT01771705

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose adjust group (NFAT)
Description: If the average residual expression of the 3 cytokines is \<20%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is \> 60% the CNI daily dose will be increased by 15%.
Study: NCT02236507

Intervention type: DEVICE
Group type: OTHER
Intervention: 3D high resolution anorectal manometry
Description: Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
Study: NCT04947748

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral versus intravenous administration of antibacterial treatment
Description: Mode of administration of antibacterial treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral versus intravenous administration of antibacterial treatment
Description: Mode of administration of antibacterial treatment
Study: NCT02834611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceramide NanoLiposome
Description: Intravenous administration of Ceramide NanoLiposome
Study: NCT03925870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN046
Description: Eligible subjects will be enrolled and receive KN046 (3 mg/kg) monotherapy treatment until progressive disease according to RECIST 1.1, unacceptable toxicity, completion of 2 years' KN046 treatment, or withdrawal of informed consent, whichever comes first
Study: NCT01190293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maraviroc
Description: All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
Study: NCT00738803

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total hip replacement
Description: Total hip replacement typically preformed for hip arthritis
Study: NCT03299400

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contact lens sensor
Description: Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
Study: NCT02025465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol
Description: The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.~Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem
Description: The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.~Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team.
Study: NCT04238442

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A&D TM-2657W oscillometric device
Description: Assessing the accuracy of the A\&D TM-2657W oscillometric device using International Standards Organization validation protocol. This involves comparing the accuracy of the A\&D device to 2 observer mercury auscultation (gold standard).
Study: NCT01617668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCL161
Description: LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.~iv 80mg/m2
Study: NCT03879239

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vibrating capsule
Description: Vibrating Capsule administered 5 times per week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating capsule
Description: Vibrating Capsule administered 5 times per week

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrating capsule
Description: Vibrating Capsule administered 5 times per week
Study: NCT04078477

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body positioning
Description: Comparison lateral tilt bed to standard patient´s body positioning in the bed.
Study: NCT00860223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neratinib
Description: HKI-272
Study: NCT04154033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: Topical naltrexone cream (1%)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Cream
Description: Topical placebo cream
Study: NCT00620048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous CD34-positive cells (stem cells)
Description: Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intramyocardial injection of autologous CD34-positive cells (stem cells)
Description: Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.